Answers are grounded in this paper and cite their sources.
Objectives: Hyperimmune - convalescent plasma transfusion appears to be a great resource in the current SARS-CoV-2 coronavirus pandemic and seems to be one of the few effective treatment modality available. However, its efficacy is variable and dependent on antibody/plasma volume concentration. Methods & Results: This single center analysis from a forefront COVID-19 Italian hospital in 43 convalescent plasma donors demonstrated that this variability in neutralizing antibody (NAB) levels is related to the harvesting period after SARS-CoV-2 recovery and interestingly, on blood group type. Specifically, the optimal plasmaferesis time point was approximately two weeks post test negativation with a significant drop in NAB plasma levels (112±102 vs 60±26.9, p=0.003) observed at 30 days. In contrast, no correlation between NAB and IgG plasma levels was observed over time (r=0.48.). Subgroup analyses demonstrated that NAB levels where higher in male (115.1±110.7, p=0.0001) and in blood group AB (200±138.6, p=0.036) donors while group A patients (81.2±82.7, p=0.062) had the lower levels of NAB concentration. Conclusion: This analysis demonstrated that male patient with a AB blood group plasma which was donated within three weeks of convalescence contains the highest therapeutic levels of antibodies and these patients should be actively recruited to become donors.
No takes yet. Share an insight, caveat, or question.
Caimmi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: